Treatment for Chronic Lymphocytic Leukaemia(CLL) - Richard Thron - Bog

Chronic lymphocytic leukemia (CLL) stands as one of the prevalent blood cancers in the United States and North America at large. Primarily affecting individuals in the older age bracket, around 80% of CLL patients are 60 years or older.
CLL is characterized by its impact on a specific type of white blood cell known as "lymphocyte." Lymphocytes play a crucial role in the body's defense against infections, originating from the soft center of bones known as the marrow. In the case of CLL, an excessive production of lymphocytes with impaired functionality occurs.
This form of leukemia is more common among adults than any other type and generally progresses slowly, often remaining asymptomatic for an extended period. While some individuals may never require treatment, those who do can experience a slowdown in disease progression and relief from associated symptoms. The advent of early CLL diagnosis has contributed to improved life expectancy, with timely medical intervention playing a pivotal role in extending patients' lives.